Tenofovir Disoproxil Fumarate (TDF) 300mg 3 years RD therapy Chinese chronic hepatitis B (CHN) CHB multiple Nucleos(t)ide analogues (NAs) failure points pts PH4 PMS study

Trial Identifier: 201215
Sponsor: GlaxoSmithKline
NCTID:: NCT02195518
Start Date: March 2015
Primary Completion Date: August 2018
Condition: Hepatitis B

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
China Beijing, China, 100050
China Beijing, China, 100054
China Beijing, China, 100044
China Beijing, China, 100034
China Shanghai, China, 200040
China Shanghai, China, 200025
China Zhengzhou, China
China, Guangdong Guangzhou, Guangdong, China, 510060
China, Guangdong Guangzhou, Guangdong, China, 510150
China, Jilin Changchun, Jilin, China
China, Sichuan Chengdu, Sichuan, China, 610041
China, Zhejiang hangzhou, Zhejiang, China, 310000